Intravenous transfusion of BCR-activated B cells protects NOD mice from type 1 diabetes in an IL-10-dependent manner

Journal of Immunology

Volumn 179, Issue 11, 2007, Pages 7225-7232

  Hussain, Shabbir ^a   Delovitch, Terry L ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BREAKPOINT CLUSTER REGION PROTEIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; FEMALE; IMMUNOLOGICAL TOLERANCE; INCIDENCE; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE TRANSFER; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; PROTECTION; SPLEEN; SPLEEN CELL; THERAPY EFFECT; ANIMAL; BIOSYNTHESIS; CYTOLOGY; HISTOCOMPATIBILITY; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; TRANSPLANTATION;

ANIMALS; B-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; FEMALE; INJECTIONS, INTRAVENOUS; INTERLEUKIN-10; MICE; MICE, INBRED NOD; MICE, SCID; RECEPTORS, ANTIGEN, B-CELL; TRANSPLANTATION IMMUNOLOGY;

EID: 38849192507     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.11.7225     Document Type: Article

References (66)

1. Delovitch, T. L., and B. Singh. 1997. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 7: 727-738.
2. Wong, F. S., and C. A. Janeway, Jr. 1999. The role of CD4 vs. CD8 T cells in IDDM. J. Autoimmun. 13: 290-295.
3. Suarez-Pinzon, W. L., and A. Rabinovitch. 2001. Approaches to type 1 diabetes prevention by intervention in cytokine immunoregulatory circuits. Int. J. Exp. Diabetes Res. 2: 3-17.
4. Pearson, C. I., and H. O. McDevitt. 1999. Redirecting Th1 and Th2 responses in autoimmune disease. Curr. Top. Microbiol. Immunol. 238: 79-122.
5. Pennline, K. J., E. Roque-Gaffney, and M. Monahan. 1994. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin. Immunol. Immunopathol. 71: 169-175.
6. Nitta, Y., F. Tashiro, M. Tokui, A. Shimada, I. Takei, K. Tabayashi, and J. Miyazaki. 1998. Systemic delivery of interleukin 10 by intramuscular injection of expression plasmid DNA prevents autoimmune diabetes in nonobese diabetic mice. Hum. Gene Ther. 9: 1701-1707.
7. Shoda, L. K. M., D. L. Young, S. Ramanujan, C. C. Whiting, M. A. Atkinson, J. A. Bluestone, G. Eisenbarth, D. Mathis, A. Rossini, and S. Campbell. 2005. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 23: 115-126.
8. Tang, Q., and J. A. Bluestone. 2006. Regulatory T-cell physiology and application to treat autoimmunity. Immunol. Rev. 212: 217-237.
9. Sharif, S., G. A. Arreaza, P. Zucker, Q. S. Mi, J. Sondhi, O. V. Naidenko, M. Kronenberg, Y. Koezuka, T. L. Delovitch, J. M. Gombert, et al. 2001. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Nat. Med. 7: 1057-1062.
10. Hong, S., M. T. Wilson, I. Serizawa, L. Wu, N. Singh, O. V. Naidenko, T. Miura, T. Haba, D. C. Scherer, J. Wei, et al. 2001. Natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med. 7: 1052-1056.
11. Wang, B., Y. B. Geng, and C. R. Wang. CD1-restricted NKT cells protect nonobese diabetic mice from developing diabetes. 2001. J. Exp. Med. 194: 313-320.
12. Naumov, Y. N., K. S. Bahjat, R. Gausling, R. Abraham, M. A. Exley, Y. Koezuka, S. B. Balk, J. L. Strominger, M. Clare-Salzer, and S. B. Wilson. 2001. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc. Natl. Acad. Sci. USA 98: 13838-13843.
13. + T regulatory cells and T regulatory type 1 cells. Diabetes 55: 1571-1580.
14. Hauben, E., M. G. Roncarolo, U. Nevo, and M. Schwartz. 2005. Beneficial autoimmunity in type 1 diabetes mellitus. Trends Immunol. 26: 248-253.
15. Mi, Q.-S., D. Ly, P. Zucker, M. McGarry, S. Sharif, and T. L. Delovitch. 2004. Interleukin-4 but not interleukin-10 protects against spontaneous and recurrent type 1 diabetes by activated CD1d-restricted invariant natural killer T cells. Diabetes 53: 1303-1310.
16. Moore, K. W., R. de Waal Malefyt, R. L. Coffman, and A. O'Garra. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19: 683-765.
17. Ding, Y., D. Chen, A. Tarcsafalvi, R. Su, L. Qin, and J. S. Bromberg. 2003. Suppressor of cytokine signaling 1 inhibits IL-10-mediated immune responses. J. Immunol. 170: 1383-1389.
18. + cell populations in vivo and ameliorates type 1 diabetes in nonobese diabetic mice in a dose-dependent fashion. J. Immunol. 171: 2270-2278.
19. Goudy, K. S., and R. Tisch. 2005. Immunotherapy for the prevention and treatment of type 1 diabetes. Int. Rev. Immunol. 24: 307-326.
20. Dejaco, C., W. Reinisch, C. Lichtenberger, T. Waldhoer, I. Kuhn, H. Tilg, and C. Gasche. 2000. In vivo effects of recombinant human interleukin-10 on lymphocyte phenotypes and leukocyte activation markers in inflammatory bowel disease. J. Invest. Med. 48: 449-456.
21. Rachmawati, H., L. Beljaars, C. Reker-Smit, A. M. Van Loenen-Weemaes, W. I. Hagens, D. K. Meijer, and K. Poelstra. 2004. Pharmacokinetic and biodistribution profile of recombinant human interleukin-10 following intravenous administration in rats with extensive liver fibrosis. Pharm. Res. 21: 2072-2078.
22. Serreze, D. V., S. A. Fleming, H. D. Chapman, S. D. Richard, E. H. Leiter, and R. M. Tisch. 1998. B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J. Immunol. 161: 3912-3918.
23. Hussain, S., and T. L. Delovitch. 2005. Dysregulated B7-1 and B7-2 expression on nonobese diabetic B cells is associated with increased T cell costimulation and the development of insultis. J. Immunol. 174: 680-687.
24. + T cells: role of TGF-β 1. J. Immunol. 170: 5897-5911.
25. Serreze, D. V., H. D. Chapman, C. M. Post, E. A. Johnson, W. L. Suarez-Pinzon, and A. Rabinovitch. 2001. Th1 to Th2 cytokine shifts in nonobese diabetic mice: sometimes an outcome, rather than the cause, of diabetes resistance elicited by immunostimulation. J. Immunol. 166: 1352-1359.
26. Cameron, M. J., G. A. Arreaza, P. Zucker, S. W. Chensue, R. M. Strieter, S. Chakrabarti, and T. L. Delovitch. 1997. IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function. J. Immunol. 159: 4686-4692.
27. Liu, J. Y., and J. Banchereau. 1997. Regulation of B cell commitment to plasma cells or to memory B cells. Semin. Immunol. 9: 235-240.
28. Asadullah, K., W. Sterry, and H. D. Volk. 2003. Interleukin-10 therapy: review of a new approach. Pharmacol. Rev. 55: 241-269.
29. Asadullah, K., R. Sabat, M. Friedrich, H. D. Volk, and W. Sterry. 2004. Interleukin-10: an important regulatory cytokine with major impact on psoriasis. Curr. Drug Targets Inflamm. Allergy 3: 185-192.
30. Salomon, B., D. J. Lenschow, L. Rhee, N. Ashourian, B. Singh, A. Sharpe, and J. A. Bluestone. 2000. B7/CD28 costimulation is essential for the homeostasis of the CD4 CD25 immunoregulatory T cells that control autoimmune diabetes. Immunity 12: 431-440.
31. + T cell levels in NOD mice. Proc. Natl. Acad. Sci. USA 99: 12287-12292.
32. Arreaza, G. A., M. J. Cameron, A. Jaramillo, B. M. Gill, D. Hardy, K. B. Laupland, M. J. Rapoport, P. Zucker, S. Chakrabarti, S. W. Chensue, et al. 1997. Neonatal activation of CD28 signaling overcomes T cell anergy and prevents autoimmune diabetes by an IL-4-dependent mechanism. J. Clin. Invest. 100: 2243-2253.
33. Dahlen, E., G. Hedlund, and K. Dawe. 2000. Low CD86 expression in the nonobese diabetic mouse results in the impairment of both T cell activation and CTLA-4 up-regulation. J. Immunol. 164: 2444-2456.
34. Zipris, D., A. H. Lazarus, A. R., Crow, M. Hadzija, and T. L. Delovitch. 1991. Defective thymic T cell activation by concanavalin A and anti-CD3 in autoimmune nonobese diabetic mice: evidence for thymic T cell anergy that correlates with the onset of insulitis. J. Immunol. 146: 3763-3771.
35. Flavius, M., and A. C. Chan. 2006. B cell immunobiology in disease: evolving concepts from the clinic. Annu. Rev. Immunol. 24: 467-496.
36. Hussain, S., K. V. Salojin, and T. L. Delovitch. 2004. Hyperresponsiveness, resistance to B-cell receptor-dependent activation-induced cell death, and accumulation of hyperactivated B-cells in islets is associated with the onset of insulitis but not type 1 diabetes. Diabetes 53: 2003-2011.
37. Noorchashm, H., N. Noorchashm, J. Kern, S. Y. Rostami, C. F. Barker, and A. Naji. 1997. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes 46: 941-946.
38. Fillatreau, S., C. H. Sweenie, M. J. McGeachy, D. Gray, and S. M. Anderton. 2002. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3: 944-950.
39. Mizoguchi, A., E. Mizoguchi, H. Takedatsu, R. S. Blumberg, and A. K. Bhan. 2002. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 16: 219-230.
40. Mauri, C., D. Gray, N. Mushtaq, and M. Londei. 2003. Prevention of arthritis by interleukin 10-producing B cells. J. Exp. Med. 197: 489-501.
41. Wolf, S. D., B. N. Dittel, F. Hardardottir, and C. A. Janeway, Jr. 1996. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J. Exp. Med. 4: 2271-2278.
42. Wong, F. S., and L. Wen. 2005. B cells in autoimmune diabetes. Rev. Diabetic Studies 2: 121-135.
43. Lenert, P., R. Brummel, E. H. Field, and R. F. Ashman. 2005. TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J. Clin. Immunol. 25: 29-40.
44. F. Burke, A. J. Stagg, P. A. Bedford, N. English, and S. C. Knight. 2004. IL-10-producing B220 CD11c APC in mouse spleen. J. Immunol. 173: 2362-2372.
45. Hathcock, K. S., G. Laszlo, C. Pucillo, P. Linsley, and R. J. Hodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180: 631-640.
46. Chiu, P. P., A. M. Jevnikar, and J. S. Danska. 2001. Genetic control of T and B lymphocyte activation in nonobese diabetic mice. J. Immunol. 167: 7169-7179.
47. Lenschow, D. J., A. I. Sperling, M. P. Cooke, G. Freeman, L. Rhee, D. C. Decker, G. Gray, L. M. Nadler, C. C. Goodnow, and J. A. Bluestone. 1994. Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. J. Immunol. 153: 1990-1997.
48. lpr mice. FASEB J. 18: 534-536.
49. 1 mice. Lupus 12: 838-845.
50. Tian, J., D. Zekzer, L. Hanssen, Y. Lu, A. Olcott, and D. L. Kaufman. 2001. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J. Immunol. 167: 1081-1089.
51. Soukhareva, N., Y. Jiang, and D. W. Scott. 2006. Treatment of diabetes in NOD mice by gene transfer of Ig-fusion proteins into B cells: role of T regulatory cells. Cell Immunol. 240: 41-46.
52. high B lymphocytes in nonobese diabetic mice maps to diabetes susceptibility region Idd11. J. Immunol. 174: 4821-4827.
53. de Waal Malefyt, R., J. Abrams, B. Bennett, C. G. Figdor, and J. E. de Vries. 1991. Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174: 1209-1220.
54. Iwasaki, A., and B. L. Kelsall. 1999. Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells. J. Exp. Med. 190: 229-239.
55. Masuda, A., Y. Yoshikai, K. Aiba, and T. Matsuguchi. 2002. Th2 cytokine production from mast cells is directly induced by lipopolysaccharide and distinctly regulated by c-Jun N-terminal kinase and p38 pathways. J. Immunol. 169: 3801-3810.
56. Roers, A., L. Siewe, E. Strittmatter, M. Deckert, D. Schluter, W. Stenzel, A. D. Gruber, T. Krieg, K. Rajewsky, and W. Muller. 2004. T cell-specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation. J. Exp. Med. 200: 1289-1297.
57. Segal, B. M., B. K. Dwyer, and E. M. Shevach. 1998. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J. Exp. Med. 187: 537-546.
58. Moulin, V., F. Andris, K. Thielemans, C. Maliszewski, J. Urbain, and M. Moser. 2000. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J. Exp. Med. 192: 475-482.
59. Amedei, A., C. Romagnani, M. Benagiano, A. Azzurri, F. Fomia, F. Torrente, A. Plebani, M. M. D'Elios, and G. Del Prete. 2001. Preferential Th1 profile of T helper cell responses in X-linked (Bruton's) agammaglobulinemia. Eur. J. Immunol. 31: 1927-1934.
60. Lee, M. S., R. Mueller, L. S. Wicker, L. B. Peterson, and N. Sarvetnick. 1996. IL-10 is necessary and sufficient for autoimmune diabetes in conjunction with NOD MHC homozygosity. J. Exp. Med. 183: 2663-2668.
61. + regulatory T cells. J. Immunol. 177: 3695-3704.
62. Del Prete, G., M. De Carli, F. Almerigogna, M. G. Giudizi, R. Biagiotti, and S. Romagnani. 1993. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J. Immunol. 150: 353-360.
63. Akdis, C. A., T. Blesken, M. Akdis, B. Wuthrich, and K. Blaser. 1998. Role of interleukin 10 in specific immunotherapy. J. Clin. Invest. 102: 98-106.
64. Zhang, X., E. Deriaud, X. Jiao, D. Braun, C. Leclerc, and R. Lo-Man. 2007. Type I interferons protect neonates from acute inflammation through IL-10 producing B cells. J. Exp. Med. 204: 1107-1118.
65. Hardy, R. R. 2006. B-1 B cell development. J. Immunol. 177: 2749-2754.
66. 1 mice. Eur. J. Immunol. 32: 2551-2261.